Diffuse Bone Uptake of 131I and Effect on Blood Counts in a Patient With Papillary Thyroid Carcinoma and Chronic Lymphocytic Leukemia

Adrien Latgé,Mehdi Krim,Lavinia Vija,Loïc Ysebaert,Slimane Zerdoud
DOI: https://doi.org/10.1097/rlu.0000000000005119
IF: 10.6
2024-03-04
Clinical Nuclear Medicine
Abstract:A 57-year-old woman with history of chronic lymphocytic leukemia was referred to our center for adjuvant 131 I therapy following complete thyroidectomy for differentiated thyroid cancer. Posttherapeutic scintigraphy revealed atypical diffuse osteomedullar uptake. A major drop in lymphocyte count was observed, from 117.7 g/L to 4.8 g/L 8 weeks after 131 I therapy. Bone marrow uptake is presumed to be related to tracer sequestration in leukemic cells. White blood cell count normalization suggests a high sensitivity of leukemic cells to beta emission. This scintigraphic pattern may act as a pitfall for nuclear medicine physician.
radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?